Salubris’s clinical trial application for SAL0137 has been accepted
October 26, 2025
Source: drugdu
133
On the evening of October 15, Xinlitai(002294) issued an announcement stating that the company received an acceptance notice approved and issued by the National Medical Products Administration, and the clinical trial application of the company's independently developed innovative small molecule drug SAL0137 tablets (project code: SAL0137) was accepted.
Xinlitai said that SAL0137 is a product developed by the company with independent intellectual property rights.The company's application for SAL0137, an oral small molecule drug, is for clinical trials for the treatment of elevated lipoprotein (a).
https://finance.eastmoney.com/a/202510153535045923.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
